| Li, Ning |
NCT04351867: A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer |
|
|
| Not yet recruiting | 3 | 196 | RoW | docetaxel plus oxaliplatin and capecitabine, Three medicine combined, oxaliplatin plus capecitabine, Two medicine combined | LiNing | Stomach Neoplasms | 06/24 | 06/24 | | |
NCT06658353: Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors |
|
|
| Not yet recruiting | 3 | 54 | RoW | VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor | 12/26 | 12/26 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT03950271: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 25 | RoW | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine | Henan Cancer Hospital | Gastric Cancer | 01/24 | 12/26 | | |
NCT04341857: PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | PD-1 Monoclonal Antibody(Sintilimab) | Henan Cancer Hospital | Gastric and Esophagogastric Junction Adenocarcinoma | 05/22 | 07/22 | | |
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors |
|
|
| Not yet recruiting | 2 | 770 | NA | Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rare Tumor | 07/22 | 07/23 | | |
NCT04062058: A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 82 | RoW | SIB-IMRT, S-1, SOX, Surgery | Jing Jin, M.D., Beijing Hope Run | Gastric Cancer, Neoadjuvant Therapy | 09/22 | 09/23 | | |
NeoTOP, NCT06618014: Neoadjuvant Toripalimab Plus Liposomal Paclitaxel and Carboplatin in Patients With Localized TNBC |
|
|
| Recruiting | 2 | 46 | RoW | Toripalimab, Liposomal paclitaxel, Carboplatin | Sun Yat-sen University | Breast Cancer, Triple Negative Breast Cancer | 03/25 | 03/28 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT06322095: A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 72 | RoW | PD-1, MET inhibitor, ALK inhibitor, BRAF Inhibito, EGFR Monoclonal antibody, GH21, MEK Inhibitor | Suzhou Genhouse Bio Co., Ltd. | Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations | 09/25 | 12/25 | | |
NCT06490068: Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy |
|
|
| Recruiting | 2 | 10 | RoW | LTC004+Toripalimab, LTC004 combine with Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 03/26 | 03/26 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Not yet recruiting | 2 | 15 | RoW | ES014, ES014 for Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Elpiscience (Suzhou) Biopharma, Ltd. | Advanced Solid Tumor | 06/26 | 09/26 | | |
| Not yet recruiting | 2 | 42 | RoW | Neratinib tablets, Epilepsy | Convalife (Shanghai) Co., Ltd. | NSCLC | 12/24 | 12/25 | | |
NCT04348643: Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer |
|
|
| Recruiting | 1/2 | 40 | RoW | CEA CAR-T cells | Chongqing Precision Biotech Co., Ltd | Solid Tumor, Lung Cancer, Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Gastric Cancer, Breast Cancer | 12/23 | 04/24 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
| Recruiting | 1/2 | 134 | US, RoW | PRO1160 | ProfoundBio US Co. | Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma | 11/26 | 03/27 | | |
NCT06612632: Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials |
|
|
| Recruiting | 1/2 | 100 | RoW | research drug in combination with Toripalimab, Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cancer | 06/26 | 06/28 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05538195: Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 60 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreatic Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 354 | US, RoW | PRO1184, PRO1184 intravenous infusion of PRO1184 | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 10/25 | 04/26 | | |
NCT06088004: Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 218 | RoW | ABO2011 Injection, ABO2011, ABOD2011, Toripalimab | Suzhou Abogen Biosciences Co., Ltd., Abogen Biosciences (Shanghai) Co., Ltd | Solid Tumor, Adult | 12/26 | 12/27 | | |
NCT04615312: A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors |
|
|
| Recruiting | 1 | 50 | RoW | a CDK4 / 6 inhibitor and a MEK inhibitor | Henan Cancer Hospital | Digestive System Tumors | 08/21 | 08/22 | | |
NCT04326296: The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer |
|
|
| Not yet recruiting | 1 | 33 | RoW | PD-L1 Monoclonal Antibody Combined With Lenalidomide | LiNing | Colorectal Neoplasms | 09/22 | 03/23 | | |
NCT05881525: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | TC-N201 cells, IL-2, Fludarabine, Cyclophosphamide, Nab-paclitaxel | TCRCure Biopharma Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumors | 10/24 | 03/25 | | |
NCT06205082: A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor |
|
|
| Enrolling by invitation | 1 | 81 | RoW | LIT-00814 | LittDD Medicines Ltd | Advanced Solid Tumor | 10/25 | 06/26 | | |
KSX01-R08-102, NCT06150365: Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 12 | RoW | KSX01-TCRT cell therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Refractory Solid Tumors, Relapsed Solid Tumors | 12/26 | 12/28 | | |
NCT05152212: Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy |
|
|
| Completed | 1 | 33 | RoW | LVGN7409 | Lyvgen Biopharma Holdings Limited | Cancer | 12/23 | 12/23 | | |
NCT06342336: HS-IT101 Injection in the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 44 | RoW | HS-IT101 Injection, HS-IT101 | Qingdao Sino-Cell Biomedicine Co., Ltd., Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Hospital of Jilin University, West China Hospital | Solid Tumor | 03/26 | 03/28 | | |
| Recruiting | 1 | 60 | RoW | BT02 monoclonal antibody injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05183243: GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results |
|
|
| Recruiting | 1 | 68 | RoW | GH21 Capsule | Suzhou Genhouse Bio Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Neoplasm | 12/24 | 02/25 | | |
NCT06328673: A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 160 | US, RoW | DM919, Pembrolizumab, Keytruda | D2M Biotherapeutics Inc. | Advanced Solid Tumor | 12/25 | 03/26 | | |
NCT06346041: Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 19 | RoW | Oncolytic Virus injection(IDOV-SAFETM) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Neoplasms | 12/24 | 04/26 | | |
| Recruiting | 1 | 112 | RoW | TQB3006 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 03/25 | 08/26 | | |
| Terminated | 1 | 3 | RoW | TQB2928 injection, Penpulimab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Neoplasm | 07/24 | 07/24 | | |
NCT06410131: Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 |
|
|
| Not yet recruiting | 1 | 68 | RoW | FTL008.16 | Sound Biopharmaceuticals Ltd. | Solid Tumors | 01/26 | 05/27 | | |
NCT05886868: Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 66 | RoW | BL0020 | Shanghai Best-Link Bioscience, LLC | Advanced Solid Tumor | 07/24 | 02/25 | | |
| Not yet recruiting | 1 | 30 | NA | JYB1907, TGF-β inhibitor | Jemincare | Solid Tumor | 09/24 | 10/24 | | |
NCT06001684: Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IBR854 Cell Injection | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Solid Tumors | 09/24 | 12/24 | | |
NCT06610227: A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients with Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 18 | NA | SapRNA™-MICA/B Tumor Vaccine | NING LI | Advanced Solid Tumors | 10/25 | 10/26 | | |
| Recruiting | 1 | 122 | RoW | SG1827 | Hangzhou Sumgen Biotech Co., Ltd. | Advanced Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 100 | RoW | HQP1351 | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult | 12/24 | 12/26 | | |
NCT05392699: ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy |
|
|
| Recruiting | 1 | 60 | RoW | human single chain IL-12 mRNA-single dose, human single chain IL-12 mRNA-multiple dose | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Patients With Advanced Solid Tumors | 03/25 | 01/27 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
| Recruiting | 1 | 71 | RoW | TQB2103 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Neoplasm | 05/25 | 05/25 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors |
|
|
| Recruiting | 1 | 18 | RoW | IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection | Suzhou Immunofoco Biotechnology Co., Ltd | Advanced Digestive System Tumor | 12/25 | 12/25 | | |
NCT06314542: Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data |
|
|
| Recruiting | N/A | 50000 | RoW | relaxing eligibility criteria | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, AstraZeneca | Lung Cancer | 12/25 | 06/26 | | |
NCT04891900: TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 25 | RoW | TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine, PD-L1 inhibitor/Anlotinib | Henan Cancer Hospital | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 12/24 | 12/24 | | |
NCT05458778: Detection of Urinary Human Chorionic Gonadotropin (hCG) |
|
|
| Recruiting | N/A | 200 | US | Daily test with urine by the product | Quanovate Tech Inc. | Pregnancy Detection | 10/23 | 10/23 | | |
NCT05609058: The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target |
|
|
| Recruiting | N/A | 300 | RoW | dedicated treatment board with no degree | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 11/23 | 11/23 | | |
| Recruiting | N/A | 6 | RoW | QH104 Cell injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Solid Tumor, Meningeal Metastasis | 12/26 | 12/27 | | |
| Not yet recruiting | N/A | 74 | NA | Circum-psoas Block, Sham block | The Second Hospital of Shandong University | Acute Pain, Opioid Use | 04/25 | 05/25 | | |
NCT06509490: NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors |
|
|
| Recruiting | N/A | 9 | RoW | KD-025 cell injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Safety Issues | 07/24 | 03/26 | | |
| Huang, Jing |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT06194734: A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer |
|
|
| Recruiting | 3 | 490 | RoW | KC1036, Irinotecan, Docetaxel, S-1, Tegafur-gimeracil-oteracil potassium | Beijing Konruns Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinoma | 12/26 | 12/27 | | |
NCT05838573: Metformin Treatment on Cognitive Impairment of Schizophrenia |
|
|
| Recruiting | 3 | 120 | RoW | Metformin treatment, Placebo treatment, Baseline assessments, Volunteer assessments | Central South University, Shandong Mental Health Center, The Second People's Hospital of Dali Bai Autonomous Prefecture, Jiangyin No.3 People's Hospital | Schizophrenia | 07/25 | 12/25 | | |
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 190 | RoW | HX008, Investigator's Choice Chemotherapy | Taizhou Hanzhong biomedical co. LTD | Metastatic Colorectal Cancer | 01/26 | 10/28 | | |
| Not yet recruiting | 2 | 120 | RoW | bear bile pill, placebo | Shanghai Mental Health Center | Major Depressive Disorder | 03/22 | 03/22 | | |
NCT04886271: Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors |
|
|
| Active, not recruiting | 2 | 210 | RoW | HX009 | Waterstone Hanxbio Pty Ltd | Advanced Solid Tumor | 12/22 | 02/23 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients |
|
|
| Active, not recruiting | 2 | 170 | US, RoW | OQL011, Vehicle Ointment | OnQuality Pharmaceuticals (USA) LLC | Hand-Foot Skin Reaction (HFSR) | 02/24 | 06/24 | | |
NCT06154538: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 170 | RoW | Cadonilimab, 1, FOLFOX regimen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Locally Advanced Colorectal Carcinoma | 11/26 | 11/28 | | |
| Not yet recruiting | 2 | 80 | NA | AK104, Cadonilimab, Cisplatin, DDP, Paclitaxel, PTX | Chinese Academy of Medical Sciences, Akeso Pharmaceuticals, Inc. | Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | 04/24 | 10/24 | | |
NCT05648006: First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer |
|
|
| Terminated | 2 | 7 | RoW | OH2, Capecitabine, Bevacizumab | Binhui Biopharmaceutical Co., Ltd. | Advanced Colorectal Carcinoma | 04/24 | 04/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Recruiting | 1 | 228 | RoW | Recombinant Humanized Monoclonal Antibody MIL93 | Beijing Mabworks Biotech Co., Ltd. | Advanced Malignancies | 08/25 | 08/25 | | |
NCT06205082: A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor |
|
|
| Enrolling by invitation | 1 | 81 | RoW | LIT-00814 | LittDD Medicines Ltd | Advanced Solid Tumor | 10/25 | 06/26 | | |
NCT06143007: A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 42 | RoW | BB3008 tablet, BB3008 | BrodenBio Co., Ltd. | Advanced Solid Tumor | 11/25 | 04/26 | | |
NCT06512116: A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients. |
|
|
| Recruiting | 1 | 196 | RoW | SIBP-A17, Her2-ADC | Shanghai Institute Of Biological Products | Advanced Solid Tumor | 07/25 | 12/25 | | |
NCT05783063: iTBS for Increased Appetite Induced by Antipsychotics |
|
|
| Recruiting | N/A | 60 | RoW | Active iTBS, Sham iTBS | Central South University | Schizophrenia | 08/25 | 12/25 | | |
NCT05795829: Ultrasound Ablation for Essential Hypertension（FIM） |
|
|
| Recruiting | N/A | 10 | RoW | disposable intravascular ultrasound ablation catheter and ultrasound ablation instrument | Lepu Medical Technology (Beijing) Co., Ltd. | Uncontrolled Essential Hypertension | 12/23 | 02/24 | | |
NCT06210100: aiTBS for NSSI and Suicide in Adolescent Depression |
|
|
| Recruiting | N/A | 60 | RoW | Active iTBS, Sham iTBS | Central South University | Non Suicidal Self Injury, Suicidal Ideation, Suicide and Self-harm | 12/24 | 02/25 | | |
NCT05384405: aiTBS for Relieving NSSI in Depressive Patients |
|
|
| Recruiting | N/A | 60 | RoW | Active iTBS, Sham iTBS | Central South University | Major Depressive Disorder, Bipolar Depression | 02/25 | 02/25 | | |
NCT06428968: Investigating the Insulin Resistance in Individuals With Type 2 Diabetes |
|
|
| Recruiting | N/A | 30 | RoW | 160 units nasal insulin spray | Central South University | Type 2 Diabetes | 12/24 | 06/25 | | |
NCT06116357: The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble |
|
|
| Not yet recruiting | N/A | 200 | RoW | External Ultrasonic Micro-bubble | Jing Huang, The Second Affiliated Hospital of Chongqing Medical University | Primary Hypertension | 09/26 | 12/26 | | |
NCT05307848: Reproductive Function in Women With Bipolar Disorder |
|
|
| Recruiting | N/A | 200 | RoW | No intervention | Central South University | Bipolar Disorder | 02/23 | 02/23 | | |
| Shi, yuankai |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
GPS, NCT05219162: Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(). |
|
|
| Completed | 4 | 182 | RoW | Gene Profile explore | AstraZeneca | Advanced NSCLC | 05/24 | 05/24 | | |
NCT03650933: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients |
|
|
| Recruiting | 3 | 360 | RoW | G-CHOP, R-CHOP | Nanjing Yoko Biomedical Co., Ltd. | Diffuse Large B-Cell Lymphoma, Unspecified Site | 08/22 | 12/25 | | |
INSPIRE, NCT04632758: Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients |
|
|
| Active, not recruiting | 3 | 292 | RoW | WX-0593 Tablets, FL-006, crizotinib | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
NCT04416035: A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC |
|
|
| Recruiting | 3 | 608 | RoW | TRS003, China-approved Bevacizumab, Carboplatin, Paclitaxel | Zhejiang Teruisi Pharmaceutical Inc. | Advanced Non-squamous Non-small-cell Lung Cancer | 10/21 | 11/21 | | |
NCT05318443: A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer |
|
|
| Completed | 3 | 512 | RoW | SIBP04, Avastin, Paclitaxel, Carboplatin | Shanghai Institute Of Biological Products, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non-squamous Non-small-cell Lung Cancer | 12/22 | 01/23 | | |
ORIENT-3, NCT03150875: A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC |
|
|
| Completed | 3 | 290 | RoW | IBI308, Docetaxel | Innovent Biologics (Suzhou) Co. Ltd. | Non-small Cell Lung Cancer | 02/23 | 02/23 | | |
|
NCT04143607: ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC |
|
|
| Active, not recruiting | 3 | 337 | RoW | ASK120067, Placebo Gefitinib 250 mg, Placebo Iressa 250 mg, Gefitinib, Placebo ASK120067 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic NSCLC | 03/24 | 09/26 | | |
NCT04044222: A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy |
|
|
| Recruiting | 3 | 240 | RoW | Sintilimab, Carboplatin, Etoposide, Ifosfamide, Placebo | Innovent Biologics (Suzhou) Co. Ltd. | Classic Hodgkin's Lymphoma | 07/23 | 12/24 | | |
HLX10-002-NSCLC301, NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 643 | RoW | HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed | Shanghai Henlius Biotech | Carcinoma, Non-Small-Cell Lung | 10/23 | 03/24 | | |
TQB2450-Ⅲ-11, NCT05346952: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). |
|
|
| Recruiting | 3 | 390 | RoW | TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Non-squamous Non-small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT03866499: A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients |
|
|
| Active, not recruiting | 3 | 369 | RoW | BPI-7711, BPI-7711 capsule, Gefitinib, Iressa, Placebo Tablet, placebo, Placebo capsule | Beta Pharma Shanghai | NSCLC | 11/23 | 12/25 | | |
NCT04834024: MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma |
|
|
| Recruiting | 3 | 168 | RoW | Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide | Beijing Mabworks Biotech Co., Ltd. | Follicular Lymphoma and Marginal Zone Lymphoma | 03/25 | 03/25 | | |
NCT06128837: Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 686 | RoW | Irinotecan hydrochloride liposome Injection, Topotecan | Luye Pharma Group Ltd. | Relapsed Small Cell Lung Cancer | 06/28 | 10/28 | | |
NCT04830813: Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer |
|
|
| Recruiting | 3 | 180 | RoW | Chiauranib, CS2164, Placebo, Simulation tablet of Chiauranib | Chipscreen Biosciences, Ltd. | Small Cell Lung Cancer | 12/24 | 12/24 | | |
| Not yet recruiting | 3 | 255 | RoW | SY-3505 Capsules, CT-3505; Ficonalkib, Crizotinib Capsules, Xalkori | Shouyao Holdings (Beijing) Co. LTD | Non-small Cell Lung Cancer | 05/26 | 05/27 | | |
NCT05294172: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 295 | RoW | KL-A167, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin injection, Placebo | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma, Recurrent or Metastatic | 05/24 | 05/25 | | |
TQB2450-III-12, NCT05718167: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. |
|
|
| Not yet recruiting | 3 | 570 | RoW | TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Squamous Non-Small Cell Lung Carcinoma | 10/24 | 10/25 | | |
NCT06658353: Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors |
|
|
| Not yet recruiting | 3 | 54 | RoW | VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor | 12/26 | 12/26 | | |
NCT04874844: JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety |
|
|
| Not yet recruiting | 2/3 | 420 | NA | Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025) | Beijing Dongfang Biotech Co., Ltd., Chinese Academy of Medical Sciences | NSCLC | 03/22 | 06/23 | | |
